Richman Chemical Inc.

11/11/2026

Richman Chemical helps emerging technology, biotech, and pharmaceutical companies develop the necessary analytical methods to accurately identify new chemical entities.

        FDA regulations require Investigational New Drug Applications (IND) that includes identity, strength, and purity data.  Richman Chemical helps emerging technology, biotech, and pharmaceutical companies develop the necessary analytical methods to accurately identify new chemical entities...

10/28/2026

Richman Chemical takes a case study approach to licensing chemistry-based technologies. How proper technology assessment, process optimization and confirmation of commercial viability can greatly increase prospective licensing and royalty values of your intellectual property.

Accurate valuations of chemistry-based technologies and intellectual property (IP) within markets such as life sciences, nanotechnology, and electronics can be a challenging task.  At the 2016 AUTM Eastern Region Meeting held in Philadelphia in September, Richman Chemical’s Senior Project Manager...

10/21/2026

Hybrid companies are an emerging alternative in the supply chain by partnering up with manufacturers by helping address any limitations as well as adding additional benefits to customers. Richman Chemical falls into this category as a "Hybrid Supplier." "Hybrid suppliers combine the best of what manufacturers and distributors have to offer along with services and customer care that help boost their customers’ bottom-line growth. And they do so without the biases and inefficiencies often exhibited by the traditional participants."

Hybrid suppliers combine the best elements of a manufacturer, distributor, and consultant to improve their customers' bottom line.

10/14/2026

RCI’s COO Chris Kulp was interviewed in Pharmaceutical Technology's article on Best practices in pharma innovation and collaboration... Learn what he had to say here.https://static1.squarespace.com/static/530e0f9be4b0769bdb4a2bd0/t/59cbac8bd55b4156e18a011b/1506520206707/Pharmaceutical+Technology+Pharma+innovation.pdf

09/23/2026

The question that university researchers or TTOs often face when developing a new product: Can we actually produce the product, at scale and in a way that makes financial sense? Learn more about solutions to this challenge. www.richmanchemical.com/s/TechnologyTransfersNews.pdf

08/28/2026

Do you need funding resources for your specialty chemical product or technology in order to commercialize?

RICHMAN CHEMICAL LAUNCHES FUNDING OPPORTUNITY REPORTS FOR START-UPS SEEKING FUNDING OR LICENSING OPPORTUNITIES IN THE LIFE SCIENCE AND SPECIALTY CHEMICAL MARKETS

08/11/2026

There are times when it makes a lot more sense to outsource in the drug development & commercialization process. We explore a variety of scenarios here.

The need for efficient “concept-to-market” strategies for product introduction in the biotech, pharmaceutical, medical device, and nanotechnology markets has never been greater. Companies in these markets operate within very tight timelines and face strict regulatory scrutiny, pressures to bring...

08/05/2026

Richman Chemical Develops New Supply of Trimethylene Carbonate for client to replace the loss in its supply chain.

Trimethylene Carbonate (TMC)

07/29/2026

Many technology start-ups risk their futures by seriously underestimating the time and effort required to vet external service suppliers. Cost effective, rapid commercialization is as essential as a quality concept. An experienced project manager is invaluable in the commercialization process and brings proprietary industry knowledge and well-established relationships throughout the entire supply chain.

Many technology start-ups risk their futures by seriously underestimating the time and effort required to vet external service suppliers.   A company's intellectual property advantages are useless if it cannot find the right resources for timely commercialization.

07/20/2026

The growth of the electronics industry and the incorporation of computer chips into consumer products is expanding the need for custom inorganic synthesis. The nanotechnology and composite material sectors often require metal-based chemistries. RCI services include inorganic and organometallic product development, scale-up, and commercial manufacturing.

The accelerating growth of the electronics industry and the incorporation of computer chips into a wider variety of consumer products are expanding the need for custom inorganic synthesis. Similar growth in the nanotechnology and composite material sectors is fueling increased demand for metal-bas...